Rectal Adenocarcinoma Clinical Trial
Official title:
(Bayer Study ONC-2013-036) A Phase II Single-Arm Study of Regorafenib Maintenance Therapy in Patients With T3, T4 or Node-Positive Rectal Cancer Patients Who Completed Curative-Intent Treatment
This phase II trial studies how well regorafenib works in reducing the return of disease in patients with rectal cancer that has not spread to another place in the body who have completed curative-intent treatment. Regorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Regorafenib may also help keep cancer from coming back after it has disappeared following the initial therapy.
PRIMARY OBJECTIVES:
I. To determine the 3-year disease free survival in patients with T3, T4 or node-positive
rectal adenocarcinoma who received regorafenib maintenance therapy following the completion
of curative-intent standard treatment.
SECONDARY OBJECTIVES:
I. To determine the cumulative incidence of local recurrence, distant recurrence and overall
survival at 3 years.
II. To explore for biomarkers associated with anti-cancer effects of regorafenib maintenance
therapy in curatively treated rectal cancer patients by analyzing tumor and blood samples.
OUTLINE:
Patients receive regorafenib orally (PO) once daily (QD) on days 1-21. Treatment repeats
every 28 days for up to 24 courses in the absence of disease progression or unacceptable
toxicity.
After completion of study treatment, patients are followed up at 30 days and then every 4
months for up to 5 years.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05081024 -
Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer
|
||
Not yet recruiting |
NCT04090450 -
Optimisation of Radiotherapy in Rectal Cancer (ORREC)
|
||
Recruiting |
NCT06050447 -
Factors Affecting the Results of Treatment of Patients With Colorectal Cancer
|
||
Terminated |
NCT02233595 -
Evaluation of Rectal Cancer Treatment Response Using PET/MRI
|
||
Completed |
NCT02935309 -
Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma
|
Phase 1 | |
Terminated |
NCT01887509 -
Evaluation of Rectal Tumor Margin Using Confocal Endomicroscopy and Comparison to Histopathology
|
N/A | |
Recruiting |
NCT05746195 -
Optimization of Adaptive Text Messages for Cancer Survivors (OATS II)
|
N/A | |
Active, not recruiting |
NCT03365882 -
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
|
Phase 2 | |
Completed |
NCT02314182 -
GRECCAR 8: Primary Tumor Resection in Rectal Cancer With Unresectable Metastasis
|
Phase 3 | |
Completed |
NCT02393755 -
Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04441580 -
Assessing the Additional Neoplasia Yield of Computer-aided Colonoscopy in a Screening Setting
|
N/A | |
Terminated |
NCT03527784 -
Prestoma-Trial for Parastomal Hernia Prevention
|
N/A | |
Completed |
NCT00855946 -
Proteomic Approach Using Matrix-assisted Laser Desorption/Ionization Tandem Time-of-flight (MALDI-TOF/TOF) of Tumor Response in Rectal Carcinoma After Radiochemotherapy
|
N/A | |
Recruiting |
NCT06328361 -
Nordic ORgan Preservation Pilot Approach Nonrandomised Single-Arm Trial for Non-Operative Management of Rectal Cancer
|
N/A | |
Recruiting |
NCT02107105 -
Evaluation of Quality of Life and Utilities Following Surgical Treatment of Stage I-IV Rectal Cancer
|
||
Terminated |
NCT03300544 -
Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03436563 -
M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04814784 -
Role of Neoadjuvent Radiotherapy in Locally Advanced Cancer Rectum
|
||
Recruiting |
NCT05482516 -
Evaluating Novel Therapies in ctDNA Positive GI Cancers
|
Phase 3 | |
Completed |
NCT02368886 -
Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
|
Phase 2 |